47th ICAAC - Interscience Conference on Antimicrobial Agents and Chemotherapy -Workshops

Register by August 17, 2007.

Preregistration is strongly recommended, as workshops are limited in attendance. On-site registration will be available for any workshops that have seats available at the close of preregistration. The workshop fee will increase by $50 for on-site registration. On-site workshop registration will be located outside room S401 on Sunday, September 16, 7:30 a.m. - 1:30 p.m.

47-01 Preclinical Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents (half-day)
8:30 AM - 12:00 Noon
Room: S402

UPN: 388-000-07-001-L01
Objectives:
At the completion of this workshop the attendee will be able to:

Compare and contrast pharmacokinetic and pharmacodynamic concepts of antimicrobial efficacy;
Apply in vitro models and animal models in pharmacodynamic research;
Recognize the limitations and use of serum and tissue concentrations; and
Calculate pharmacokinetic and pharmacodynamic parameters and interpret the results

Prerequisites: None
Course Level: Beginning
Intended Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, pharmacists, and others interested.

Conveners:
JOHAN W. MOUTON, MD, PhD; Canisius Wilhelmina Hosp., Nijmegen, The Netherlands.
HARTMUT DERENDORF, PhD; Univ. of Florida, Gainesville, FL.

Faculty:
OTTO CARS, MD, MPH; Uppsala Univ. Hosp., Uppsala, Sweden.
WILLIAM A. CRAIG, MD; Univ. of Wisconsin and VA Hosp., Madison, WI.
HARTMUT DERENDORF, PhD; Univ. of Florida, Gainesville, FL.
JOHAN W. MOUTON, MD, PhD; Canisius Wilhelmina Hosp., Nijmegen, The Netherlands.
INGA M. ODENHOLT SR., MD; Lunds Univ., Malmö, Sweden.
URSULA THEURETZBACHER, PhD; Center for Anti-Infective Agents, Vienna, Austria.

47-02 Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents (half-day)
1:00 PM - 4:30 PM
Room S403A

UPN: 388-000-07-002-L01
Objectives:
At the completion of this workshop the attendee will be able to:

Explain the clinical significance of pharmacokinetic and pharmacodynamic modeling of antimicrobials;
Apply preclinical PK/PD concepts to clinical drug development;
Evaluate PK/PD of antivirals and antifungals;
Assess effects of drug exposure at the site of infection; and
Evaluate clinical drug resistance

Prerequisites: None
Course Level: Intermediate/Advanced
Intended Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, pharmacists, and others interested.

Convener:
JOHAN W. MOUTON, MD, PhD; Canisius Wilhelmina Hosp., Nijmegen, The Netherlands.

Faculty:
DAVID R. ANDES, MD; University of Wisconsin Medical School, Madison, WI
OTTO CARS, MD, MPH; Uppsala Univ. Hosp., Uppsala, Sweden.
JOHAN W. MOUTON, MD, PhD; Canisius Wilhelmina Hosp., Nijmegen, The Netherlands.
PAUL M. TULKENS, MD,PhD; Catholic University of Louvain, Brussels, Belgium
GEORGE L. DRUSANO, MD; Ordway Res. Inst., Albany, NY.
CHRISTIAN JOUKHADAR, MD; Vienna University Medical School, Vienna, Austria

UPN: 388-000-07-003-L01
Objectives:
At the completion of this workshop the attendee will be able to:

Discuss MIC based PK/PD modeling in vitro and in animals;
Distinguish PK/PD based on kill curves;
Interpret population PK/PD of anti-infective agents;
Explain Monte Carlo Simulations; and
Assess integration of preclinical and clinical PK/PD

Prerequisites: None
Course Level: Intermediate/Advanced
Intended Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, pharmacists, and others interested.

Faculty:
WILLIAM A. CRAIG, MD; Univ. of Wisconsin and VA Hosp., Madison, WI.
HARTMUT DERENDORF, PhD; Univ. of Florida, Gainesville, FL.
GEORGE L. DRUSANO, MD; Ordway Res. Inst., Albany, NY.
ALAN FORREST, PharmD; State Univ. of New York Sch. of Pharmacy, Buffalo, NY.
ALASDAIR P. MACGOWAN, MD; Bristol Ctr. for Antimicrobial Res. and Evaluation, Westbury-on-Trym, United Kingdom.
HUI C. KIMKO, PhD; Advanced Modeling & Simulation, Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ

UPN: 388-000-07-004-L01
Objective: This workshop allows the attendee to refresh his/her knowledge of the basics in the area of PK/PD before they move on to the more advanced concepts relating to the preclinical aspects of the PK/PD of Anti-Infective Agents.
At the completion of this workshop the attendee will be able to:

Compare and contrast pharmacokinetic and pharmacodynamic concepts of antimicrobial efficacy;
Apply in vitro models and animal models in pharmacodynamic research;
Recognize the limitations and use of serum and tissue concentrations;
Calculate pharmacokinetic and pharmacodynamic parameters and interpret the results;
Explain the clinical significance of pharmacokinetic and pharmacodynamic modeling of antimicrobials;
Apply preclinical PK/PD concepts to clinical drug development;
Evaluate PK/PD of antivirals and antifungals;
Assess effects of drug exposure at the site of infection; and
Evaluate clinical drug resistance.

Prerequisites: None
Course Level: Beginning/Intermediate/Advanced
Intended Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, pharmacists, and others interested.
Conveners:
JOHAN W. MOUTON, MD, PhD; Canisius Wilhelmina Hosp., Nijmegen, The Netherlands.
HARTMUT DERENDORF, PhD; Univ. of Florida, Gainesville, FL.
Faculty:
TBA, please visit www.icaac.org for complete faculty list.

UPN: 388-000-07-005-L01
Objective: This workshop allows the attendee to refresh his/her knowledge of the basics in the area of PK/PD before they move on to the more advanced concepts of PK/PD Modeling of Anti-Infective Agents.
At the completion of this workshop the attendee will be able to:

Compare and contrast pharmacokinetic and pharmacodynamic concepts of antimicrobial efficacy;
Apply in vitro models and animal models in pharmacodynamic research;
Recognize the limitations and use of serum and tissue concentrations;
Calculate pharmacokinetic and pharmacodynamic parameters and interpret the results;
Discuss MIC based PK/PD modeling in vitro and in animals;
Distinguish PK/PD based on kill curves;
Interpret population PK/PD of anti-infective agents;
Explain Monte Carlo Simulations; and
Assess integration of preclinical and clinical PK/PD.

Prerequisites: None
Course Level: Beginning/Intermediate/Advanced
Intended Audience: Medical microbiologists, infectious diseases specialists, pharmacologists, pharmacists, and others interested.
Conveners:
HARTMUT DERENDORF, PhD; Univ. of Florida, Gainesville, FL.
JOHAN W. MOUTON,MD, PhD; Canisius Wilhelmina Hosp., Nijmegen, The Netherlands.
Faculty:
Please see list above.

47-06 Antibiotic Resistance among Bacterial Pathogens: Mechanisms, Detection, and Molecular Epidemiology
8:30 AM - 4:30 PM

UPN: 388-000-07-006-L01
This intermediate level workshop will address important mechanisms of antibiotic resistance among common bacterial pathogens (VISA, hVISA, MRSA, VRE, MDRSP, ESBL, amp(C), KPC-producing Enterobacteriaceae, etc). The workshop will also explain the mechanisms of resistance for selected classes of antibiotics as well as the PK/PD parameters of these compounds that assist in evaluating potential clinical efficacy. The session will conclude with a discussion on the epidemiology of antimicrobial resistance both from an evolutionary and a molecular perspective.

At the completion of this workshop the attendee will be able to:

Describe the important antimicrobial resistance mechanisms of problematic bacterial pathogens;
Recommend laboratory techniques most appropriate for detection of such mechanisms of resistance;
Discuss the PK/PD parameters used to evaluate antimicrobial agents in the light of evolving resistance; and
Recognize the various molecular and evolutionary approaches used to track the development antibiotic resistance.

Prerequisites: None
Course Level: Intermediate
Intended Audience: Clinical microbiologists, infectious disease physicians, clinical pharmacists with expertise and interest in infectious diseases, infection control practitioners, and clinical microbiology laboratory supervisors.
Convener:
STEPHEN G. JENKINS, PhD; Mount Sinai Sch. of Med., New York, NY.
Faculty:
STEPHEN G. JENKINS, PhD; Mount Sinai Sch. of Med., New York, NY.

47-07 Monitoring, Evaluating and Managing Antimicrobial Use in Hospitals
Developed in Cooperation with the ESCMID Study Group on Antibiotic Policies (ESGAP)
8:30 AM - 4:30 PM

UPN: 388-000-07-007-L01
This workshop will provide the theoretical foundation and the practical information and tools to measure, evaluate and manage antimicrobial use in hospitals. The morning session includes methods for data collection, analysis and interpretation of consumption data in the individual hospital, as well as within multicenter networks. The afternoon session presents strategies from successful antimicrobial management programs, methods to audit the quality of antimicrobial prescriptions, a critical review of different intervention strategies to improve antimicrobial use in health care facilities and the role of newer information technology to help antimicrobial drug use.
At the completion of this workshop the attendee will be able to:

Identify sources of data and calculate the volume of antimicrobial use in a hospital;
Select proper measurement units for antimicrobial use;
Interpret antimicrobial use data locally and within a multicenter network;
Choose and to apply an audit methodology for monitoring the quality of antimicrobial prescriptions;
Identify possible interventions—and their relative advantages and disadvantages-- which could be implemented in a hospital;
Identify the electronic antimicrobial drug prescribing aids and the advantages and disadvantages of each; and
Describe how an individual hospital can determine if its antimicrobial management program was economically successful and if it had an impact on bacterial resistance.

Prerequisites: None
Course Level: Intermediate
Intended Audience: Infectious diseases pharmacists, infection control practitioners involved in antimicrobial management, and infectious diseases physicians
Conveners:
RONALD E. POLK, PharmD; Virginia Commonwealth Univ., Richmond, VA.
INGE C. GYSSENS, MD, PhD; Erasmus Univ. Med. Ctr., Rotterdam, The Netherlands.
Faculty:
RONALD E. POLK, PharmD; Virginia Commonwealth Univ., Richmond, VA.
DOMINIQUE L. MONNET, PharmD, PhD; Statens Serum Inst., Copenhagen, Denmark.
INGE C. GYSSENS, MD, PhD; Erasmus Univ. Med. Ctr., Rotterdam, The Netherlands.
HAROLD C. STANDIFORD, MD; Univ. of Maryland, Baltimore, MD.
ROBERT P. GAYNES, MD; CDC, Atlanta, GA.
RICHARD H. DREW, PharmD, MS; Duke Univ. Med. Ctr., Durham, NC.

47-08 Molecular Typing of Bacteria: Generation, Analysis of Data, and Interpretation of Results
8:30 AM - 4:30 PM

UPN:388-000-07-008-L04
At the completion of this educational activity, participants will be able to apply various methods for molecular typing of bacteria. Participants will be able to analyze and interpret generated typing data. Resources available for analysis and interpretation will be discussed. Demonstrations of selected resources will be presented.
At the completion of this workshop the attendee will be able to:

Give an overview of available typing techniques;
Explain how to compare different typing methods;
Apply PFGE to type bacteria;
Describe the principles of ribotyping;
Apply AFLP to type bacteria;
Apply and develop a MLVA scheme to type bacteria;
Describe the principles of RAPD/ERIC;
Apply and develop a MLST scheme to type bacteria;
Apply SLST (spa, M-protein, MAST) to type bacteria;
Describe micro-array techniques for typing of bacteria;
Operate different resources (e.g. eBURST, START) to analyze typing results; and
Explain emerging typing techniques and future challenges.

Prerequisites: Basic knowledge of PCR, DNA sequencing, and PFGE.
Course Level: Intermediate
Intended Audience: Clinical microbiologists, medical technologists, supervisors, managers, directors, pathologists, physicians, pharmaceutical industry QC, educators, epidemiologists and infectious disease specialists.
Conveners:
DAG HARMSEN, MD; Univ. of Münster, Münster, Germany.
ALEXANDER MELLMAN, MD; Univ. of Münster, Münster, Germany.
Faculty:
RICHARD V. GOERING, PhD; Creighton Univ. Med. Ctr., Omaha, NE.
DAG HARMSEN, MD; Univ. of Münster, Münster, Germany.
ALEXANDER MELLMAN, MD; Univ. of Münster, Münster, Germany.
ALEX VAN BELKUM, PhD; Erasmus Med. Ctr., Rotterdam, The Netherlands.
ROB J.L. WILLEMS, PhD; Univ. Med. Ctr., Utrecht, The Netherlands.

47-09 Clinical Mycology: Practical Information for the Clinician
8:30 AM - 4:30 PM

UPN: 388-000-07-009-L04
This workshop is intended to provide clinicians with timely and useful information relating to the diagnosis, interpretation of in vitro activity data, and management of patients with fungal infections. Information relating to yeast and mould pathogens will be discussed.
At the completion of this workshop the attendee will be able to:

Summarize the pharmacology and pharmacokineitcs/pharmacodynamics of existing and investigational antifungal agents
Discuss the significance of the results of recently published clinical trials assessing the safety, efficacy, and economics of antifungal therapies
Discuss the advantages and limitations of various techniques used to assess the in vitro and in vivo activity of antifungal agents against yeasts and moulds
Review the mechanisms of antifungal resistance reported in yeasts and moulds, and discuss the clinical significance of antifungal resistance
Summarize published treatment guidelines for the management of patients diagnosed with fungal infections; and
Formulate treatment strategies for patients diagnosed with a fungal infection

Prerequisites: None
Course Level: Intermediate
Intended Audience: Any clinician (i.e., physician, pharmacist, nurse practitioner, microbiologist) or researcher whose practice involves the diagnosis and management of patients infected with fungal pathogens or whose research interests lie in the area of clinical mycology.
Convener:
MICHAEL E. KLEPSER, PharmD; Ferris State Univ. Coll. of Pharmacy, Kalamazoo, MI.
Faculty:
MICHAEL E. KLEPSER, PharmD; Ferris State Univ. Coll. of Pharmacy, Kalamazoo, MI.
RUSSELL E. LEWIS, PharmD; Univ. of Houston Coll. of Pharmacy, Houston, TX.

DIMITRIOS P. KONTOYIANNIS, MD; Univ. of Texas M.D. Anderson Cancer Ctr., Houston, TX. DANIEL J. DIEKEMA, MD, MS; Univ. of Iowa Coll. of Med., Iowa City, IA.

47-10 Case Studies in Clinical Virology: Laboratory Choices and Challenges in Detecting and Monitoring Viral Infections
8:30 AM - 4:30 PM

UPN: 388-000-07-010-L04
Efficient and accurate diagnosis and monitoring of viral diseases is a challenging process that is heavily influenced by the type of specimen submitted to the clinical virology laboratory and by the methods that will be performed. This case-based workshop will review the appropriate specimen and assay choices for a variety of viral syndromes and clinical scenarios. The faculty and the workshop participants will discuss the strengths and limitations of individual tests and how they can contribute to, or detract from, an accurate viral diagnosis. This workshop will be highly interactive and attendees are encouraged to ask questions and present problems for discussion.

At the completion of this workshop the attendee will be able to:

Make appropriate specimen choices for the detection and monitoring of viral diseases;
Compare and contrast various clinical virology laboratory tests, including culture-based assays, rapid antigen tests, serology, and methods for the qualitative and quantitative detection of nucleic acids;
Select the most appropriate laboratory assay(s) to perform depending on the patient population and clinical situation and the intended use of the individual tests; and
Discuss how specimen and test utilization impacts on the interpretation of results and the accurate diagnosis and monitoring of viral diseases.

Prerequisites: None
Course Level: Intermediate
Intended Audience: Infectious disease specialists, laboratory directors, laboratory supervisors, pharmacists, medical technologists, other physicians and laboratorians.
Conveners:
RICHARD L. HODINKA, PhD; Children's Hosp. of Philadelphia, Philadelphia, PA.
DANNY L. WIEDBRAUK, PhD; Warde Med. Lab., Ann Arbor, MI.
Faculty:
RICHARD L. HODINKA, PhD; Children's Hosp. of Philadelphia, Philadelphia, PA.
DANNY L. WIEDBRAUK, PhD; Warde Med. Lab., Ann Arbor, MI.

47-11 Origin, Epidemiology, Diagnosis, and Management of CA-MRSA (half day)
Developed in Cooperation with ESCMID
8:30 AM - 12:00 PM

UPN: 388-000-07-011-L04
This workshop will address key features of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The possible origins of CA-MRSA, the transmission and spread of these clones, and the genotypic and phenotypic properties that distinguish them from those commonly found in hospitals will be discussed. Appropriate methods for detecting MRSA and clinical implications of detecting CA-MRSA will be reviewed. The impact of CA-MRSA on treatment and selection of appropriate antimicrobial therapy for community-onset infections caused by S. aureus will be discussed.
At the completion of this workshop the attendee will be able to:

Compare and contrast the origins of and genotypic relationships between MRSA clones circulating in the community and in hospitals;
Describe the overlapping epidemiology of community-associated MRSA and healthcare-associated MRSA strains in the U.S.;
Select laboratory methods that are the most appropriate for the detection of MRSA isolated from clinical and screening samples; and
Select from a variety of possible antimicrobial agents those that are most appropriate for treatment of community-onset MRSA infection.

Prerequisites: None
Course Level: Intermediate
Intended Audience: Primary care and ID physicians, pharmacists, epidemiologists, and microbiologists
Conveners:
HENRY F. CHAMBERS, MD; UCSF, San Francisco, CA.
ROBERT SKOV, MD; Statens Serum Inst., Copenhagen, Denmark.
Faculty:
FRED C. TENOVER, PhD; CDC, Atlanta, GA.
ROBERT SKOV, MD; Statens Serum Inst., Copenhagen, Denmark.
HENRY F. CHAMBERS, MD; UCSF, San Francisco, CA.

Room: S501ABCD
UPN: 388-000-07-012-L02
The Workshop will introduce the participants to the recent advances in HIV research. The focus will be on describing new HIV therapies and how they will be adapted to clinical practice. In addition the current state of the art in HIV prevention including an update on HIV vaccine and microbicides will be presented. Finally the new field of pharmacogenomics and its application to clinical management of HIV will be discussed.

At the completion of this workshop the attendee will be able to:

Describe the current HIV therapies, their mechanism of action and clinical application;
Understand the current state of the art for HIV vaccines;
Understand where the field of HIV prevention is, especially with regards to microbicides; and
Understand the value of pharmacogenomics in HIV therapeutic strategies.

Prerequisites: None
Course Level: Intermediate
Intended Audience: Physicians or Scientists who would want to gain knowledge of the state of the art of HIV research in therapy and prevention.

Faculty:
RICHARD KOUP, MD; Vaccine Res. Ctr., Bethesda, MD.
MICHAEL LEDERMAN, MD; Univ. Hosp. of Cleveland, Clevland, OH.
DANIEL KURITZKES, MD; Brigham and Women’s Hosp., Cambridge, MA.
DAVID HASS, MD; Vanderbilt Univ. Med. Ctr., Nashville, TN.